Mount Sinai researchers identify genetic predictors of response to selinexor in multiple myeloma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mount Sinai researchers identified genes that predict a positive response to selinexor, a multiple myeloma therapy which can have serious side effects for some patients.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

GSK plc announced statistically significant and clinically meaningful overall survival results from a planned interim analysis of the DREAMM-7 trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone versus daratumumab in combination with bortezomib plus dexamethasone as a second line or later treatment for relapsed or refractory multiple myeloma. 
Johnson & Johnson announced new results from the phase III CARTITUDE-4 study that show a single infusion of Carvykti (ciltacabtagene autoleucel; cilta-cel) significantly increased minimal residual disease negativity rates (10-5) in patients with relapsed or refractory multiple myeloma who were lenalidomide-refractory and had received one to three prior lines of therapy, including a proteasome inhibitor, compared to standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login